Abstract
The effect of a new kappa-opioid agonist benzimidazole derivative (compound RU-1205) on the generative function of outbred male rats was studied after oral administration for 2 months at doses of 5 mg/kg – experimentally proven therapeutic dose (TD) and 500 mg/kg (the highest dose is 100 TD). The absence of a damaging effect of the compound RU-1205 on the motivational sexual behavior of males and the processes of spermatogenesis was established.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
